JP2020534540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534540A5 JP2020534540A5 JP2020516740A JP2020516740A JP2020534540A5 JP 2020534540 A5 JP2020534540 A5 JP 2020534540A5 JP 2020516740 A JP2020516740 A JP 2020516740A JP 2020516740 A JP2020516740 A JP 2020516740A JP 2020534540 A5 JP2020534540 A5 JP 2020534540A5
- Authority
- JP
- Japan
- Prior art keywords
- napi2b
- cancer
- seq
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 46
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 21
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 21
- 239000000611 antibody drug conjugate Substances 0.000 claims description 17
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 17
- 206010033128 Ovarian cancer Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
- 206010038389 Renal cancer Diseases 0.000 claims description 10
- 201000010982 kidney cancer Diseases 0.000 claims description 10
- 208000009956 adenocarcinoma Diseases 0.000 claims description 8
- 230000004043 responsiveness Effects 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 5
- 206010004593 Bile duct cancer Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 4
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 238000010191 image analysis Methods 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 101710114425 Homeobox protein Nkx-2.1 Proteins 0.000 claims description 2
- 102100027893 Homeobox protein Nkx-2.1 Human genes 0.000 claims description 2
- 101710088547 Thyroid transcription factor 1 Proteins 0.000 claims description 2
- 101710159262 Transcription termination factor 1 Proteins 0.000 claims description 2
- 230000000762 glandular Effects 0.000 claims description 2
- 238000000386 microscopy Methods 0.000 claims description 2
- -1 napsin A Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 238000000399 optical microscopy Methods 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 1
- 210000001581 salivary duct Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762561107P | 2017-09-20 | 2017-09-20 | |
| US62/561,107 | 2017-09-20 | ||
| US201762571397P | 2017-10-12 | 2017-10-12 | |
| US62/571,397 | 2017-10-12 | ||
| US201862718692P | 2018-08-14 | 2018-08-14 | |
| US62/718,692 | 2018-08-14 | ||
| PCT/US2018/051951 WO2019060542A2 (en) | 2017-09-20 | 2018-09-20 | COMPOSITIONS AND METHODS FOR PREDICTING RESPONSE TO NAPI2B TARGETING THERAPY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534540A JP2020534540A (ja) | 2020-11-26 |
| JP2020534540A5 true JP2020534540A5 (cg-RX-API-DMAC7.html) | 2021-10-28 |
| JP7279026B2 JP7279026B2 (ja) | 2023-05-22 |
Family
ID=63963394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516740A Active JP7279026B2 (ja) | 2017-09-20 | 2018-09-20 | Ｎａｐｉ２ｂ標的化療法に対する応答を予測するための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11596694B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3685166A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7279026B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200055770A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111492246A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018337947A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020005390A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3075798A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL273252B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020003214A (cg-RX-API-DMAC7.html) |
| TW (1) | TW201929906A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019060542A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3836972A1 (en) | 2018-08-17 | 2021-06-23 | Mersana Therapeutics, Inc. | Napi2b-targeted polymer antibody-drug conjugates and methods of use thereof |
| CN114585623A (zh) | 2019-08-02 | 2022-06-03 | 梅尔莎纳医疗公司 | 双[N-((5-氨基甲酰基)-1H-苯并[d]咪唑-2-基)吡唑-5-甲酰胺]衍生物和相关化合物作为STING（干扰素基因刺激物）激动剂用于治疗癌症 |
| EP4087614A1 (en) | 2020-01-09 | 2022-11-16 | Mersana Therapeutics, Inc. | Site specific antibody-drug conjugates with peptide-containing linkers |
| WO2021202984A1 (en) | 2020-04-02 | 2021-10-07 | Mersana Therapeutics, Inc. | Antibody drug conjugates comprising sting agonists |
| CN116194138A (zh) | 2020-08-07 | 2023-05-30 | 博德研究所 | 治疗性靶向癌症中经由xpr1:kidins220蛋白质复合物的磷酸盐调节异常 |
| JP7589759B2 (ja) * | 2021-02-08 | 2024-11-26 | 株式会社島津製作所 | 推定装置 |
| WO2024082056A1 (en) * | 2022-10-19 | 2024-04-25 | Zymeworks Bc Inc. | Anti-napi2b antibodies and methods of use |
| KR20250089499A (ko) * | 2022-10-19 | 2025-06-18 | 자임워크스 비씨 인코포레이티드 | Napi2b를 표적화하는 항체-약물 접합체 및 사용 방법 |
| TW202530268A (zh) * | 2023-10-19 | 2025-08-01 | 加拿大商酵活英屬哥倫比亞有限公司 | 抗ｎａｐｉ２ｂ抗體－藥物結合物及使用方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3900534A1 (de) * | 1989-01-10 | 1990-07-12 | Boehringer Mannheim Gmbh | Diagnostischer nachweis unter verwendung von chimaeren antikoerpern |
| CH694588A5 (de) | 1999-02-09 | 2005-04-15 | Hoffmann La Roche | Menschliche intestinale Npt2B. |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| WO2003060086A2 (en) | 2002-01-15 | 2003-07-24 | Board Of Regents, The University Of Texas System | Napi type iib polypeptides and methods for making and using same |
| KR101438983B1 (ko) | 2003-11-06 | 2014-09-05 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
| JP4861308B2 (ja) * | 2004-04-07 | 2012-01-25 | ジェネンテック， インコーポレイテッド | 抗体結合体の質量分析 |
| RU2404810C9 (ru) * | 2004-06-01 | 2015-06-20 | Дженентек, Инк. | Конъюгаты антитело-лекарственное средство и способы |
| US8383799B2 (en) * | 2006-01-20 | 2013-02-26 | Cell Signaling Technology, Inc. | Translocation and mutant ROS kinase in human non-small cell lung carcinoma |
| WO2008051980A2 (en) | 2006-10-25 | 2008-05-02 | Wisconsin Alumni Research Foundation | Methods of reducing phosphate absorption |
| EP2250201B1 (en) | 2008-01-29 | 2014-04-30 | Ludwig Institute for Cancer Research Ltd. | Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy |
| ES2547552T3 (es) * | 2008-02-01 | 2015-10-07 | Genentech, Inc. | Metabolito de nemorrubicina y reactivos análogos, conjugados anticuerpo-fármaco y métodos |
| CN102159248B (zh) | 2008-07-15 | 2013-09-11 | 健泰科生物技术公司 | 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途 |
| JP5370826B2 (ja) * | 2009-04-20 | 2013-12-18 | 株式会社パソロジー研究所 | 癌の組織型を判別するカクテル抗体、判別キット及び判別方法 |
| CA2781887C (en) | 2009-11-30 | 2018-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| WO2012006473A1 (en) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| EP2590656B1 (en) | 2010-07-07 | 2017-11-15 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| JP5827328B2 (ja) | 2010-07-07 | 2015-12-02 | アーデリクス，インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
| EP2590965B1 (en) | 2010-07-07 | 2016-04-20 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| EP2654769B1 (en) * | 2010-12-14 | 2020-04-15 | Recepta Biopharma S.A. | Antitumor peptide derived from a complementarity determining region of a humanized monoclonal antibody to napi2b transporter |
| TWI597065B (zh) * | 2011-06-10 | 2017-09-01 | 梅爾莎納醫療公司 | 蛋白質－聚合物－藥物共軛體 |
| CN105813655B (zh) | 2013-10-11 | 2022-03-15 | 阿萨纳生物科技有限责任公司 | 蛋白-聚合物-药物缀合物 |
| CN105979970B (zh) * | 2013-10-11 | 2019-09-10 | 梅尔莎纳医疗公司 | 蛋白质-聚合物-药物共轭物 |
| CN106488768A (zh) * | 2014-04-25 | 2017-03-08 | 埃克塞里艾克西斯公司 | 治疗肺腺癌的方法 |
| TWI695011B (zh) * | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗ｈｅｒ２表位之單株抗體及其使用之方法 |
| ES2810856T3 (es) | 2015-06-03 | 2021-03-09 | Bristol Myers Squibb Co | Anticuerpos ANTI-GITR para diagnóstico de cáncer |
| EP3322735A4 (en) * | 2015-07-15 | 2019-03-13 | Zymeworks Inc. | ACTIVE CONJUGATED BIS-SPECIFIC ANTIGEN-BONDING CONSTRUCTS |
| WO2017068097A1 (en) * | 2015-10-23 | 2017-04-27 | Roche Diagnostics Gmbh | Methods of identifying an individual as to be treated by chemotherapy based on marker molecules and related uses |
| US20170261766A1 (en) | 2016-03-14 | 2017-09-14 | Vance M. Thompson | Contact lens with flexible center and rigid periphery |
| US10287259B2 (en) | 2016-03-14 | 2019-05-14 | The Penn State Research Foundation | Selenazolidine and thiazolidine compounds for treating cancer and other diseases |
| CA3016474A1 (en) * | 2016-03-15 | 2017-09-21 | Mersana Therapeutics, Inc. | Napi2b-targeted antibody-drug conjugates and methods of use thereof |
| CN111315414A (zh) | 2017-06-22 | 2020-06-19 | 梅尔莎纳医疗公司 | 产生载药聚合物支架和蛋白-聚合物-药物缀合物的方法 |
-
2018
- 2018-09-20 KR KR1020207011297A patent/KR20200055770A/ko not_active Abandoned
- 2018-09-20 EP EP18792596.1A patent/EP3685166A2/en not_active Withdrawn
- 2018-09-20 JP JP2020516740A patent/JP7279026B2/ja active Active
- 2018-09-20 IL IL273252A patent/IL273252B2/en unknown
- 2018-09-20 WO PCT/US2018/051951 patent/WO2019060542A2/en not_active Ceased
- 2018-09-20 CN CN201880074734.0A patent/CN111492246A/zh active Pending
- 2018-09-20 MX MX2020003214A patent/MX2020003214A/es unknown
- 2018-09-20 US US16/136,706 patent/US11596694B2/en active Active
- 2018-09-20 TW TW107133186A patent/TW201929906A/zh unknown
- 2018-09-20 AU AU2018337947A patent/AU2018337947A1/en not_active Abandoned
- 2018-09-20 BR BR112020005390-2A patent/BR112020005390A2/pt not_active IP Right Cessation
- 2018-09-20 CA CA3075798A patent/CA3075798A1/en active Pending
-
2023
- 2023-01-26 US US18/160,012 patent/US20230355787A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534540A5 (cg-RX-API-DMAC7.html) | ||
| Oude Munnink et al. | Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF‐α experience to oncology | |
| IL273252B1 (en) | Compositions and methods for predicting response to napi2b-targeted therapy | |
| CN105392800A (zh) | 抗cxcl1、cxcl7和cxcl8抗体及其应用 | |
| ES2753360T3 (es) | Anticuerpos contra PD-L1 y usos de los mismos | |
| CN103154741B (zh) | 含有抗体作为成分的医药品的有效性的判定方法 | |
| Pollock et al. | Increased expression of HER2, HER3, and HER2: HER3 heterodimers in HPV-positive HNSCC using a novel proximity-based assay: implications for targeted therapies | |
| JP2015529199A5 (cg-RX-API-DMAC7.html) | ||
| CN104755501A (zh) | 与赖氨酰氧化酶样蛋白2(loxl2)相关的治疗和诊断方法 | |
| US20210341490A1 (en) | Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies | |
| JP2014517259A (ja) | 胃癌患者の生存期間を予測及び改善する方法 | |
| JP2020510409A5 (cg-RX-API-DMAC7.html) | ||
| JP6940505B2 (ja) | 組成物および癌の発生リスクの評価方法 | |
| JP2014523920A5 (cg-RX-API-DMAC7.html) | ||
| RU2017136863A (ru) | Способы лечения рака легкого | |
| RU2014138586A (ru) | Прогностический биомаркер для лечения рака антителами с повышенной антителозависимой клеточной цитотоксичностью | |
| KR20210126057A (ko) | 암세포에 존재하는 케라틴 14(krt14)의 세포외 부분을 표적화함으로써 암을 치료하거나 예방하는 방법 | |
| Buchholz et al. | Prostaglandin E2 receptor EP1 expression in vulvar cancer | |
| EP3485281A1 (en) | Method and means for detecting the level of total vegf-a | |
| JP2018516877A5 (cg-RX-API-DMAC7.html) | ||
| JP2018520366A5 (cg-RX-API-DMAC7.html) | ||
| KR20180013878A (ko) | 렌바티닙 및 에베로리무스를 포함하는 병용 요법을 위한 생체표지 | |
| US12433951B2 (en) | Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin | |
| JP5548872B2 (ja) | 大腸がん肝転移マーカー、及び試料中の大腸がん肝転移マーカーの分析方法 | |
| JP7593669B2 (ja) | コンパニオン診断用バイオマーカー組成物およびこれを含むコンパニオン診断用キット |